Protalix Biotherapeutics Inc
F:PBDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Protalix Biotherapeutics Inc
F:PBDA
|
US |
|
CTS Corp
F:XT1
|
US |
|
M
|
Mitsui Chemicals Inc
XMUN:MSI
|
JP |
|
S
|
Shin-Etsu Chemical Co Ltd
XMUN:SEH
|
JP |
|
O
|
Omnicell Inc
F:OC9
|
US |
|
Italian Wine Brands S.P.A.
F:MR3
|
IT |
|
H
|
Harvard Bioscience Inc
F:HBI
|
US |
|
Atlanta Braves Holdings Inc
F:E450
|
US |
|
Yamaha Motor Co Ltd
F:YMA0
|
JP |
|
Delta Electronics Thailand PCL
SET:DELTA
|
TH |
|
MAP Aktif Adiperkasa Tbk PT
IDX:MAPA
|
ID |
|
A
|
Active Biotech AB publ
F:BTPC
|
SE |
|
A
|
Avolta AG
XMUN:D2J
|
CH |
|
E
|
Eastman Chemical Co
F:EAC
|
US |
|
Entra ASA
F:2EN
|
NO |
|
Atoss Software AG
F:AOF
|
DE |
|
SRT Marine Systems PLC
LSE:SRT
|
UK |
|
H
|
Harmony Gold Mining Company Ltd
JSE:HAR
|
ZA |
Wall St Price Targets
PBDA Price Targets Summary
Protalix Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for PBDA is 8.378 EUR with a low forecast of 7.541 EUR and a high forecast of 9.408 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PBDA's stock price target?
Price Target
8.378
EUR
According to Wall Street analysts, the average 1-year price target for PBDA is 8.378 EUR with a low forecast of 7.541 EUR and a high forecast of 9.408 EUR.
What is the Revenue forecast for Protalix Biotherapeutics Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 3 years is 10%.
What is the Gross Profit forecast for Protalix Biotherapeutics Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 6 years is 7%.
